M Tiseo

Summary

Affiliation: University of Parma
Country: Italy

Publications

  1. doi request reprint Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?
    Cecilia Bozzetti
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 5:551-3. 2010
  2. ncbi request reprint MET and ALK as Targets for the Treatment of NSCLC
    M Capelletti
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Curr Pharm Des 20:3914-32. 2014
  3. pmc Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
    C Boni
    Oncology Unit, S Maria Nuova Hospital, Viale Risorgimento 80, Reggio Emilia 42123, Italy
    Br J Cancer 106:658-65. 2012
  4. ncbi request reprint Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Via Gramsci 14, 43100, Parma, Italy
    Cancer Chemother Pharmacol 73:299-307. 2014
  5. doi request reprint Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
    Marcello Tiseo
    Oncology Unit, University Hospital, Parma, Italy Electronic address
    Lung Cancer 83:265-71. 2014
  6. pmc Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
    Andrea Cavazzoni
    Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
    Mol Cancer 11:91. 2012
  7. pmc ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
    M Tiseo
    Oncology Unit, University Hospital, Via Gramsci 14, 43126 Parma, Italy
    Br J Cancer 108:1695-703. 2013
  8. doi request reprint Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma, Italy
    Tumori 98:594-600. 2012
  9. doi request reprint Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial
    Andrea Ardizzoni
    Azienda Ospedaliero Universitaria, Parma, Italy
    J Clin Oncol 30:4501-7. 2012
  10. doi request reprint Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
    Marcello Tiseo
    Division of Oncology, University Hospital of Parma, Parma, Italy
    Lung Cancer 78:92-9. 2012

Collaborators

Detail Information

Publications44

  1. doi request reprint Is cytology reliable for epidermal growth factor receptor gene evaluation in non-small cell lung cancer?
    Cecilia Bozzetti
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 5:551-3. 2010
    ..Epidermal growth factor receptor (EGFR) gene copy number has been proposed as predictor of response to epidermal growth factor receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer (NSCLC)...
  2. ncbi request reprint MET and ALK as Targets for the Treatment of NSCLC
    M Capelletti
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Curr Pharm Des 20:3914-32. 2014
    ..This review will discuss the MET and ALK pathways, the different strategies of their inhibition and the potential approaches to overcome acquired resistance to kinase inhibitors in these two genes. ..
  3. pmc Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB-IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST)
    C Boni
    Oncology Unit, S Maria Nuova Hospital, Viale Risorgimento 80, Reggio Emilia 42123, Italy
    Br J Cancer 106:658-65. 2012
    ....
  4. ncbi request reprint Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Via Gramsci 14, 43100, Parma, Italy
    Cancer Chemother Pharmacol 73:299-307. 2014
    ..The aim of this study was to evaluate the predictive value of PET response after 2 days of erlotinib in unselected pretreated patients with stage IV NSCLC...
  5. doi request reprint Correlation between erlotinib pharmacokinetics, cutaneous toxicity and clinical outcomes in patients with advanced non-small cell lung cancer (NSCLC)
    Marcello Tiseo
    Oncology Unit, University Hospital, Parma, Italy Electronic address
    Lung Cancer 83:265-71. 2014
    ..The purposes of this study were to characterize erlotinib pharmacokinetic and to correlate drug serum and urine levels to toxicity and outcomes in advanced NSCLC patients...
  6. pmc Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
    Andrea Cavazzoni
    Department of Clinical and Experimental Medicine, University of Parma, Parma, Italy
    Mol Cancer 11:91. 2012
    ..ErbB/HER-targeting by monoclonal antibodies such as cetuximab and trastuzumab or tyrosine-kinase inhibitors as gefitinib or erlotinib has been proven effective in the treatment of advanced NSCLC...
  7. pmc ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin
    M Tiseo
    Oncology Unit, University Hospital, Via Gramsci 14, 43126 Parma, Italy
    Br J Cancer 108:1695-703. 2013
    ..The prognostic and predictive effect of ERCC1/BRCA1 expression and ERCC1/XPD/XRCC1-3 gene polymorphisms on outcomes of patients was examined...
  8. doi request reprint Asymptomatic pulmonary embolism in lung cancer: prevalence and analysis of clinical and radiological characteristics in 141 outpatients
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, Parma, Italy
    Tumori 98:594-600. 2012
    ..Such a high prevalence suggests the importance to pay more attention to pulmonary embolism prevention in this population...
  9. doi request reprint Pemetrexed versus pemetrexed and carboplatin as second-line chemotherapy in advanced non-small-cell lung cancer: results of the GOIRC 02-2006 randomized phase II study and pooled analysis with the NVALT7 trial
    Andrea Ardizzoni
    Azienda Ospedaliero Universitaria, Parma, Italy
    J Clin Oncol 30:4501-7. 2012
    ..To compare efficacy of pemetrexed versus pemetrexed plus carboplatin in pretreated patients with advanced non-small-cell lung cancer (NSCLC)...
  10. doi request reprint Pharmacogenetic study of patients with advanced non-small cell lung cancer (NSCLC) treated with second-line pemetrexed or pemetrexed-carboplatin
    Marcello Tiseo
    Division of Oncology, University Hospital of Parma, Parma, Italy
    Lung Cancer 78:92-9. 2012
    ..To correlate candidate polymorphisms affecting pemetrexed and carboplatin activity with clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated in second-line with pemetrexed or pemetrexed plus carboplatin...
  11. pmc Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
    Roberta R Alfieri
    Department of Experimental Medicine, Unit of Experimental Oncology, University of Parma, Parma, Italy
    Mol Cancer 10:143. 2011
    ..The primary site of gefitinib metabolism is the liver, nevertheless tumor cell metabolism can significantly affect treatment effectiveness...
  12. doi request reprint Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Expert Rev Anticancer Ther 11:1677-87. 2011
    ..This article will present knowledge on the characteristics of ALK-positive patients, discuss the different methods of ALK rearrangement detection and focus on clinical results of crizotinib...
  13. pmc Maintenance therapy in NSCLC: why? To whom? Which agent?
    Silvia Novello
    Thoracic Oncology Unit, University of Turin, AOU, San Luigi Orbassano, Italy
    J Exp Clin Cancer Res 30:50. 2011
    ....
  14. doi request reprint Endometrial metastasis of lung adenocarcinoma: a case report
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Tumori 97:411-4. 2011
    ..We report the first case, to our knowledge, of non-small cell lung cancer with metastatic spread to the endometrium...
  15. doi request reprint EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations
    M Tiseo
    Medical Oncology Unit, University Hospital of Parma, Italy
    Lung Cancer 71:241-3. 2011
    ..Considering this report, ALK status should be investigated in unexplained cases of EGFR-TKI-resistance of EGFR mutated NSCLCs...
  16. pmc Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC)
    M Tiseo
    Medical Oncology Unit, University, Hospital of Parma, Parma, Italy
    Drug Des Devel Ther 4:81-98. 2010
    ..As a result, gefitinib is expected to have a large impact on the management of patients with advanced NSCLC, in particular in EGFR mutated patients...
  17. doi request reprint Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 67:355-60. 2010
    ..Moreover, EGFR gene copy number and, potentially, also EGFR intron 1 polymorphism could aid in better prediction of EGFR TKI responsiveness in advanced NSCLC...
  18. doi request reprint First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Expert Rev Anticancer Ther 9:425-35. 2009
    ..This review will discuss this new evidence in the first-line treatment of advanced NSCLC, focusing on different possible therapeutic approaches according to histologic subtype...
  19. ncbi request reprint Typhlitis during second-line chemotherapy with pemetrexed in non-small cell lung cancer (NSCLC): A case report
    Marcello Tiseo
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Lung Cancer 65:251-3. 2009
    ..We present a case of typhlitis in a patient with advanced non-small cell lung cancer (NSCLC) who received pemetrexed, as second-line chemotherapy treatment...
  20. doi request reprint An expanded access program of erlotinib (Tarceva) in patients with advanced non-small cell lung cancer (NSCLC): data report from Italy
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliero Universitaria, Parma, Italy
    Lung Cancer 64:199-206. 2009
    ..TRUST is a phase IV trial initiated to provide erlotinib access to patients with advanced NSCLC. We report the interim analysis for patients enrolled in the TRUST trial in Italy...
  21. doi request reprint Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Italy
    J Thorac Oncol 3:1104-11. 2008
    ..This study was designed to assess the role of (CA)n polymorphism in predicting the outcome of gefitinib treatment in advanced non-small cell lung cancer (NSCLC)...
  22. ncbi request reprint Refractory pleural small cell carcinoma in never smoker. A case report
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliera Universitaria, Parma, Italy
    Tumori 94:434-6. 2008
    ..This case of a refractory pleural small cell carcinoma, which is an extremely rare disease, is the first reported in a never smoker and the first to be fully characterized for EGFR status...
  23. ncbi request reprint Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancer
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci, 14, 43100 Parma, Italy
    Anticancer Res 28:507-13. 2008
    ..The predictive and prognostic role of neuron-specific enolase (NSE) in non-small cell lung cancer (NSCLC) is still under debate...
  24. ncbi request reprint Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma
    Marcello Tiseo
    Division of Medical Oncology, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Tumori 93:138-44. 2007
    ..In our Institutions, cisplatin chemotherapy is an outpatient treatment that provides adequate hydration with an NaCl solution plus furosemide and diuresis monitoring during treatment...
  25. ncbi request reprint Current status of second-line treatment and novel therapies for small cell lung cancer
    Marcello Tiseo
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 2:764-72. 2007
    ..This review provides an update of clinical research on second-line chemotherapy of SCLC and of recent results obtained with novel molecular targeted approaches in both first- and second-line therapy...
  26. ncbi request reprint Multi-target inhibitors in non-small cell lung cancer (NSCLC)
    M Tiseo
    Oncologia Medica, Azienda Ospedaliera Universitaria, Parma, Italy
    Ann Oncol 17:ii55-57. 2006
  27. doi request reprint Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients
    C Tibaldi
    Division of Oncology, Department of Oncology, Azienda USL 6 of Livorno, Italy
    Ann Oncol 23:670-7. 2012
    ....
  28. ncbi request reprint Novel targeted approaches in non-small cell lung cancer (NSCLC)
    A Ardizzoni
    Azienda Ospedaliera Universitaria, Parma, Italy
    Ann Oncol 17:v91-3. 2006
  29. doi request reprint Advantages of multidetector-row CT with multiplanar reformation in guiding percutaneous lung biopsies
    M De Filippo
    Dipartimento di Scienze Cliniche, Sezione di Scienze Radiologiche, Universita degli Studi di Parma, Parma, Italy
    Radiol Med 113:945-53. 2008
    ....
  30. doi request reprint Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines
    Silvia La Monica
    Department of Experimental Medicine, University of Parma, Via Volturno 39, 43100 Parma, Italy
    Biochem Pharmacol 78:460-8. 2009
    ..These data suggest that treatment with everolimus and gefitinib might be of value in the treatment of selected NSCLC patients that exhibit high tumor proliferative activity...
  31. ncbi request reprint Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    A Ardizzoni
    Azienda Ospedaliera Universitaria, Parma, Italy
    J Chemother 16:104-7. 2004
    ..Future developments are likely to value poli-chemotherapy or combination chemotherapy with EGFR tyrosine kinase inhibitors in second-line treatment of advanced NSCLC...
  32. ncbi request reprint Combination of target agents: challenges and opportunities
    Andrea Ardizzoni
    Department of Oncology, Azienda Ospedaliero, Universitaria di Parma, Parma, Italy
    J Thorac Oncol 2:S4-6. 2007
  33. ncbi request reprint Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
    Federico Cappuzzo
    Division of Medical Oncology, Bellaria Hospital, Via Altura 3, 40139 Bologna, Italy
    Lung Cancer 41:227-31. 2003
    ..We report four cases of Brain Metastases (BM) from non-small cell lung cancer (NSCLC) responding to ZD 1839 therapy after standard therapy failure...
  34. ncbi request reprint Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis
    Andrea Ardizzoni
    Division of Medical Oncology, University Hospital, Via Gramsci 14, 43100 Parma, Italy
    J Natl Cancer Inst 99:847-57. 2007
    ..Because the efficacy of carboplatin and cisplatin in the treatment of advanced non-small-cell lung cancer (NSCLC) has not been proven to be equivalent, an individual patient data meta-analysis comparing the two treatments was performed...
  35. doi request reprint Comparison between epidermal growth factor receptor (EGFR) gene expression in primary non-small cell lung cancer (NSCLC) and in fine-needle aspirates from distant metastatic sites
    Cecilia Bozzetti
    Division of Medical Oncology, University Hospital of Parma, Parma, Italy
    J Thorac Oncol 3:18-22. 2008
    ..The possibility to perform FISH analysis on cytologic material obtained by fine-needle aspiration from superficial and visceral metastases would allow us to know the real EGFR status avoiding invasive diagnostic procedures...
  36. ncbi request reprint Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung cancer
    Andrea Ardizzoni
    Division of Medical Oncology, University Hospital of Parma, Parma, Italy
    Cancer 107:2842-9. 2006
    ....
  37. doi request reprint Grading the neuroendocrine tumors of the lung: an evidence-based proposal
    G Rindi
    Institute of Anatomic Pathology, Università Cattolica del Sacro Cuore Policlinico A Gemelli, Rome, Italy Service of Biometry and Clinical Epidemiology, Research Department, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy Service of Pathology, Centro Diagnostico Italiano, Milan, Italy Thoracic Unit, Department of Surgery, University of Parma, Parma, Italy Medical Oncology Unit, University Hospital of Parma, Parma, Italy Unit of Pathological Anatomy, Centre for Molecular and Translational Oncology, University Hospital, University of Parma, Parma, Italy Medical Oncology Unit of Respiratory Tract and Sarcomas, Department of Medical Oncology, European Institute of Oncology, Milan, Italy Division of Thoracic Surgery, European Institute of Oncology, Milan, Italy Department of Thoracic Surgery, Università Cattolica del Sacro Cuore Policlinico A Gemelli, Rome, Italy Division of Pathology, University of Turin at San Luigi Hospital, Orbassano, Torino, Italy Division of Thoracic Surgery, European Institute of Oncology, University of Milan School of Medicine, Milan, Italy Division of Pathology and Laboratory Medicine, European Institute of Oncology
    Endocr Relat Cancer 21:1-16. 2014
    ..A three-tiers grading system based on Ki67 index, mitotic count, and necrosis with cutoffs specifically generated for lung neuroendocrine tumors is prognostically effective and accurate. ..
  38. ncbi request reprint Localized malignant pleural mesothelioma: report of two cases
    Silvia Tanzi
    Oncologia Medica, Azienda Ospedaliero Universitaria di Parma, Parma, Italy
    J Thorac Oncol 4:1038-40. 2009
    ..Both cases demonstrate that the localized malignant mesothelioma should be distinguished from diffuse form and that complete resection is associated with good prognosis...
  39. ncbi request reprint Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer
    Maura Loprevite
    Medical Oncology A, National Institute for Cancer Research, S Martino Hospital, Genoa, Italy
    Clin Cancer Res 13:6518-26. 2007
    ..Expression of the same proteins was also assessed on corresponding tissue samples for comparison. Moreover, EGFR gene mutations and copy number were analyzed...
  40. ncbi request reprint Induction chemotherapy with carboplatin-paclitaxel followed by standard radiotherapy with concurrent daily low-dose cisplatin plus weekly paclitaxel for inoperable non-small-cell lung cancer
    Andrea Ardizzoni
    Division of Medical Oncology A, Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
    Am J Clin Oncol 28:58-64. 2005
    ..More active and less toxic combined modality treatments need to be developed for inoperable NSCLC...
  41. ncbi request reprint Predictors of clinical response of non-small cell cancer to gefitinib
    Andrea Ardizzoni
    JAMA 291:1563; author reply 1563-4. 2004
  42. ncbi request reprint Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC)
    Francesco Grossi
    Division of Medical Oncology A, Disease Management Team Lung Cancer, National Institute for Cancer Research, L go R Benzi 10, 16132 Genova, Italy
    Crit Rev Oncol Hematol 58:221-30. 2006
    ..This review summarizes the present knowledge on the use of granulocyte growth factors in NSCLC...
  43. ncbi request reprint Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: does cisplatin versus carboplatin make a difference?
    Marcello Tiseo
    J Clin Oncol 23:6276-7; author reply 6277-8. 2005
  44. ncbi request reprint In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines
    Maura Loprevite
    Oncologia Medica A, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
    Oncol Res 15:39-48. 2005
    ..In conclusion, our experiments indicate that CI-994 is a promising novel cytostatic for the treatment of NSCLC. Its use in combination with standard anticancer agents, such as gemcitabine and docetaxel, is warranted...